Fresenius Kabi launches generic Trisenox
Fresenius Kabi is introducing its arsenic trioxide injection in a 10 mg per 10 mL vial presentation.
The product is the first-to-market generic of Teva's Trisenox, which is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia, or APL, who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression.
“With the introduction of arsenic trioxide injection, Fresenius Kabi is pleased to continue to expand its broad oncology portfolio, providing patients and clinicians with access to affordable generic alternatives of vital medicines,” Fresenius Kabi USA president and CEO John Ducker said. “We’re also pleased to bring back the original 10 mg per 10 mL (1mg per mL) presentation of arsenic trioxide injection — now in a vial presentation — to provide a familiar alternative to clinicians.”
The product is the first-to-market generic of Teva's Trisenox, which is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia, or APL, who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression.
“With the introduction of arsenic trioxide injection, Fresenius Kabi is pleased to continue to expand its broad oncology portfolio, providing patients and clinicians with access to affordable generic alternatives of vital medicines,” Fresenius Kabi USA president and CEO John Ducker said. “We’re also pleased to bring back the original 10 mg per 10 mL (1mg per mL) presentation of arsenic trioxide injection — now in a vial presentation — to provide a familiar alternative to clinicians.”